← All trials
NCT04579640
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 27, 2020
- Primary completion
- Jun 30, 2021
- Completion date
- Jun 30, 2021
- First posted
- Oct 8, 2020
- Last posted
- Dec 1, 2020
- Enrollment
- 6200
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LondonLead sponsor
- Barts & The London NHS TrustCollaborator
- Pharma NordCollaborator
- Barts & The London NHS TrustCollaborator
- Cytoplan LtdCollaborator
- Fischer Family TrustCollaborator
- The AIM FoundationCollaborator
- Synergy Biologics LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.